心血管疾患における遺伝子検査の応用
Alexandra Smirnova1, Mario Urtis, Eloisa Arbustini
1Centre for Inherited Cardiovascular Diseases, Department of Clinical and Experimental Research, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Current opinion in cardiology
|February 24, 2026
まとめ
心血管疾患(CVD)の遺伝子検査は、遺伝的発見の増加により極めて重要である。本レビューは、遺伝性CVDの種類、検査、限界、および診断向上のための将来の方向性を網羅する。
科学分野:
- 心血管遺伝学
- 医療ゲノム学
- 疾患病態生理学
背景:
- 多数の心血管疾患(CVD)の遺伝的基礎がますます特定されている。
- これにより、臨床的な遺伝子検査の需要が大幅に増加した。
- 遺伝性CVDの認識は、表現型、画像診断、機能的研究の進歩を促進した。
研究 の 目的:
- 主要な遺伝性心血管疾患群をレビューする。
- CVDに対する現在の遺伝子検査戦略を要約する。
- 診断精度のための限界と将来の展望を議論する。
主な方法:
- 遺伝性心血管疾患に関する包括的な文献レビュー。
- 現在の遺伝子検査方法論とその限界の分析。
- 心血管遺伝学における将来の方向性の探求。
主要な成果:
- メンデル遺伝性CVDは、心筋症、不整脈、動脈疾患などを含む。
- ミトコンドリア病も心血管系への関与を示す。
- 遺伝子検査は、「オールインワン」ソリューションを目指し、アクセスを改善する。
結論:
- 主な課題には、技術的限界、結果の解釈、検査の完全性が含まれる。
- 学際的なアプローチと技術革新が不可欠である。
- 将来の開発は、心血管遺伝学における診断精度の向上を優先する。
関連する概念動画
Pharmacogenomics: Identification of New Drug Targets
49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Genome-wide Association Studies-GWAS
15.9K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.9K
Principles of Pharmacogenetics: Types of Genetic Variants
54
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
54
Coronary Artery Disease I: Introduction
1.3K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
Genetic Screens
5.8K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
57
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57


